Semnur Pharmaceuticals, Inc. (SMNR)
PNK · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, a novel viscous gel formulation of corticosteroid to treat lumbosacral radicular pain, or sciatica, which is in the second Phase 3 study. The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company.
Peers in Healthcare
Semnur Pharmaceuticals, Inc. has no peer companies in this window.
Recent press releases
Semnur Pharmaceuticals, Inc. has not issued a press release in this window.
SEC filings
All filings →Semnur Pharmaceuticals, Inc. has not filed an SEC document in this window.
Insider trades
All insider trades →Semnur Pharmaceuticals, Inc. has no reported insider trades in the last 90 days.
Institutional holders
All holders →No 13F holdings have been reported for Semnur Pharmaceuticals, Inc. in this window.
People at Semnur Pharmaceuticals, Inc.
All people →Quarterly financials
Full financials →No quarterly financials have been ingested for Semnur Pharmaceuticals, Inc..